Biogen Idec Inc's Fortress Is Pricey Real Estate
Biogen is building an incredible MS business, but expectations are very high today
Here's How Regeneron Plans to Repeat Eylea's Success
Regeneron hopes cholesterol drug alirocumab can diversify its revenue beyond Elyea.
Amgen Inc's Deep Pipeline Offsets Some of the Price Risk
Amgen's high-quality pipeline offsets some of the sector-wide price risk.
Merck Leads Health Care's Bounce as the Dow Jumps Almost 200 Points
Johnson & Johnson and Merck rank among the Dow's leaders on a great day for investors across the markets.
Dividend Stock To Watch Today: Sanofi
This is why investors should get Sanofi on their watchlist.